Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Leukemia and lymphoma are 2 common hematologic cancers in adolescents and young adults (AYAs, age 15-39 years at diagnosis); however, this population has historically had lower clinical trial enrollment and less dramatic improvements in overall survival compared to other age populations. Several unique challenges to delivering care to this population have affected drug development, clinical trial availability, accessibility, and acceptance, all of which impact clinical trial enrollment. Recently, several national and institutional collaborative approaches have been utilized to improve trial availability and accessibility for AYAs with hematologic malignancies. In this review, we discuss the known barriers to cancer clinical trial enrollment and potential approaches and solutions to improve enrollment for AYAs with leukemia and lymphoma on clinical trials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665597 | PMC |
http://dx.doi.org/10.1182/hematology.2024000526 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!